PL1740200T3 - IL-6 do terapii lub zapobiegania neuropatii wywołanej chemioterapią - Google Patents

IL-6 do terapii lub zapobiegania neuropatii wywołanej chemioterapią

Info

Publication number
PL1740200T3
PL1740200T3 PL05737409T PL05737409T PL1740200T3 PL 1740200 T3 PL1740200 T3 PL 1740200T3 PL 05737409 T PL05737409 T PL 05737409T PL 05737409 T PL05737409 T PL 05737409T PL 1740200 T3 PL1740200 T3 PL 1740200T3
Authority
PL
Poland
Prior art keywords
chemotherapy
therapy
prevention
induced neuropathy
neuropathy
Prior art date
Application number
PL05737409T
Other languages
English (en)
Inventor
Michel Dreano
Pierre-Alain Vitte
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of PL1740200T3 publication Critical patent/PL1740200T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL05737409T 2004-04-29 2005-04-28 IL-6 do terapii lub zapobiegania neuropatii wywołanej chemioterapią PL1740200T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL16167304A IL161673A0 (en) 2004-04-29 2004-04-29 Compositions and methods for therapy of chemotherapy-induced neuropathy
PCT/IL2005/000444 WO2005105135A1 (en) 2004-04-29 2005-04-28 Il-6 for therapy or prevention of chemotherapy-induced neuropathy
EP05737409.2A EP1740200B1 (en) 2004-04-29 2005-04-28 Il-6 for therapy or prevention of chemotherapy-induced neuropathy

Publications (1)

Publication Number Publication Date
PL1740200T3 true PL1740200T3 (pl) 2018-04-30

Family

ID=34074041

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16188978T PL3124040T3 (pl) 2004-04-29 2005-04-28 IL-6 do terapii lub zapobiegania neuropatii wywołanej chemioterapią
PL05737409T PL1740200T3 (pl) 2004-04-29 2005-04-28 IL-6 do terapii lub zapobiegania neuropatii wywołanej chemioterapią

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16188978T PL3124040T3 (pl) 2004-04-29 2005-04-28 IL-6 do terapii lub zapobiegania neuropatii wywołanej chemioterapią

Country Status (11)

Country Link
US (1) US7951359B2 (pl)
EP (2) EP3124040B1 (pl)
JP (1) JP2007534746A (pl)
AU (1) AU2005237324A1 (pl)
CA (1) CA2564390A1 (pl)
DK (2) DK3124040T3 (pl)
ES (2) ES2788131T3 (pl)
IL (2) IL161673A0 (pl)
NO (1) NO20065471L (pl)
PL (2) PL3124040T3 (pl)
WO (1) WO2005105135A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL163856A0 (en) 2004-09-01 2005-12-18 Applied Research Systems Use of IL-6 in vascular complications
US8372389B2 (en) 2007-11-28 2013-02-12 Hadasit Medical Research Services And Development Ltd. Methods for the treatment of radiation or chemotherapy-induced tissue damage
WO2012037283A2 (en) * 2010-09-14 2012-03-22 Mount Sinai School Of Medicine Admimistration of sns neuroprotective agents to promote hematopoietic regeration
EP3299032A1 (en) 2016-09-23 2018-03-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Inhibitors of gpr132 for use in preventing and/or treating chemotherapy-induced neuropathic pain
WO2019221528A1 (en) * 2018-05-17 2019-11-21 Helixmith Co., Ltd. Treatment of neuropathic pain associated with chemotherapy-induced peripheral neuropathy
WO2022256688A1 (en) * 2021-06-04 2022-12-08 Sonnet BioTherapeutics, Inc. Methods of treating age-related frailty with interleukin-6

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
AU645294B2 (en) 1989-12-22 1994-01-13 Merck Serono Sa Endogenous gene expression modification with regulatory element
KR100234520B1 (ko) 1991-01-18 1999-12-15 그레고리 아보트 종양괴사인자 매개병 치료용 의약품 조성물
IT1247484B (it) 1991-03-22 1994-12-17 Ceinge Societa Consortile A R Metodo per la preparazione di interleuchina 6
WO1994003492A1 (en) 1992-08-06 1994-02-17 The University Of Melbourne Interleukin-6 variants and uses therefor
IT1263022B (it) 1992-11-06 1996-07-23 Angeletti P Ist Richerche Bio Interleuchina-6 mutante con attivita' biologica migliorata rispetto all'interleuchina-6 selvatica.
IT1261787B (it) 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
WO1997016202A1 (en) * 1995-10-27 1997-05-09 Amrad Operations Pty. Ltd. Cytokines and their use in treatment and/or prophylaxis of breast cancer
ATE403001T1 (de) * 1996-05-22 2008-08-15 Viventia Biotech Inc Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
CA2281493A1 (en) * 1997-02-20 1998-08-27 David S. Dime Site-specific drug delivery
IT1291932B1 (it) * 1997-06-20 1999-01-21 Angeletti P Ist Richerche Bio Composizioni farmaceutiche antitumorali capaci anche di ridurre la farmacoresistenza in cellule tumorali, in particolare di carcinoma
IL122818A0 (en) 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
WO2001003737A1 (en) 1999-07-13 2001-01-18 Bolder Biotechnology Inc. Immunoglobulin fusion proteins
WO2003033015A1 (en) * 2001-10-11 2003-04-24 Applied Research Systems Ars Holding N.V. USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY
IL163856A0 (en) * 2004-09-01 2005-12-18 Applied Research Systems Use of IL-6 in vascular complications

Also Published As

Publication number Publication date
DK3124040T3 (da) 2020-04-20
WO2005105135A8 (en) 2006-12-07
US20080193409A1 (en) 2008-08-14
EP1740200B1 (en) 2017-11-22
PL3124040T3 (pl) 2020-08-24
EP3124040A1 (en) 2017-02-01
JP2007534746A (ja) 2007-11-29
NO20065471L (no) 2007-01-09
ES2657049T3 (es) 2018-03-01
IL178636A0 (en) 2007-02-11
WO2005105135A1 (en) 2005-11-10
ES2788131T3 (es) 2020-10-20
DK1740200T3 (en) 2018-01-08
CA2564390A1 (en) 2005-11-10
EP3124040B1 (en) 2020-02-12
AU2005237324A1 (en) 2005-11-10
EP1740200A1 (en) 2007-01-10
IL161673A0 (en) 2004-09-27
US7951359B2 (en) 2011-05-31

Similar Documents

Publication Publication Date Title
IL268462A (en) Dosage form of risedronate
EP1753428A4 (en) INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
HK1105415A1 (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
IL181896A0 (en) Methods and compositions for the treatment of hyperlipidemia
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
EP1799865A4 (en) PROCESS FOR THE ADMINISTRATION OF ILOPERIDONE
EP1789034A4 (en) COMPOUNDS HAVING A DIPHENYL STRUCTURE FOR THE TREATMENT OF IMMUNE DISEASES
ZA200703087B (en) Methods and compositions for the treatment of hyperlipidemia
IL182993A0 (en) Treatment of mastitis
GB0427455D0 (en) Dosage forms
PL1740200T3 (pl) IL-6 do terapii lub zapobiegania neuropatii wywołanej chemioterapią
SI1814572T1 (sl) Depsipeptidi za preprečevanje vertikalnih endoparazitskih infekcij
GB0420424D0 (en) Therapeutic compounds
IL178635A0 (en) Compositions and methods for therapy of chemotherapy-induced neuropathy
ZA200606780B (en) Compounds for the treatment of diseases
GB0417560D0 (en) Therapeutic compounds
IL177531A0 (en) Compounds for the treatment of diseases
GB0420867D0 (en) Compounds for the treatment of diseases
GB0425073D0 (en) Compounds for the treatment of diseases
GB0425064D0 (en) Compounds useful for the treatment of diseases
AP2006003743A0 (en) Compounds useful for the treatment of diseases
IL179092A0 (en) Spiroderivatives for the treatment of hypertension
GB0420063D0 (en) Therapeutic compounds
GB0403988D0 (en) Therapeutic compounds